Fibroblast growth factor 23 - a phosphate regulating hormone;Fibroblast growth factor 23 - et fosfatregulerende hormon

Ugeskrift for Laeger

Volumn 172, Issue 20, 2010, Pages

  Beck Nielsen, Signe Sparre ^a   Pedersen, Susanne Møller ^a   Kassem, Moustapha ^a   Andersen, Lars Melholt Rasmussen HC ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE;

BLOOD; CALCINOSIS; DIFFERENTIAL DIAGNOSIS; FIBROUS DYSPLASIA; HOMEOSTASIS; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; NEOPLASM; PHYSIOLOGY; REVIEW; X LINKED HYPOPHOSPHATEMIC RICKETS;

BIOLOGICAL MARKERS; CALCINOSIS; DIAGNOSIS, DIFFERENTIAL; FIBROBLAST GROWTH FACTORS; FIBROUS DYSPLASIA OF BONE; HOMEOSTASIS; HUMANS; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; NEOPLASMS; PHOSPHATES;

EID: 77953399717     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hanson A. An elementary chemical study of the parathyreoid glands of cattle. Milit Surg 1923;52:280-4.
2. Collip JP. Extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J Biol Chem 1925;63:395-438.
3. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-8.
4. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770-4.
5. Mirams M, Robinson BG, Mason RS et al. Bone as a source of FGF23: regulation by phosphate? Bone 2004;35:1192-9.
6. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.
7. Li SA, Watanabe M, Yamada H et al. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 2004;29:91-9.
8. Saito H, Kusano K, Kinosaki M et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 2003;278:2206-11.
9. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007;18:1637-47.
10. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003-8.
11. Shimada T, Urakawa I, Yamazaki Y et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004;314:409-14.
12. Bai X, Miao D, Li J et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004;145:5269-79.
13. Saito H, Maeda A, Ohtomo S et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005;280:2543-9.
14. Burnett SA, Gunawardene SC, Bringhurst FR et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006;21:1187-96.
15. Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-9.
16. Nishida Y, Taketani Y, Yamanaka-Okumura H et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 2006;70:2141-7.
17. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;17:1305-15.
18. Koh N, Fujimori T, Nishiguchi S et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001;280:1015-20.
19. Westerberg PA, Linde T, Wikstrom B et al. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 2007;22:3202-7.
20. Lorenz-Depiereux B, Bastepe M, et-Pages A et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006;38:1248-50.
21. Bowe AE, Finnegan R, Jan de Beur SM et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001;284:977-81.
22. Liu S, Guo R, Simpson LG et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003;278:37419-26.
23. Liu S, Rowe PS, Vierthaler L et al. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 2007;192:261-7.
24. Rowe PS, Matsumoto N, Jo OD et al. Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone 2006;39:773-86.
25. Imel EA, Peacock M, Pitukcheewanont P et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006;91:2055-61.
26. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63.
27. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002;87:4957-60.
28. Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 2007;22:520-6.
29. Riminucci M, Collins MT, Fedarko NS et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003;112:683-92.
30. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001;98:6500-5.
31. Endo I, Fukumoto S, Ozono K et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients Proposal of diagnostic criteria using FGF23 measurement. Bone 2008;42:1235-9.
32. Ichikawa S, Imel EA, Kreiter ML et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Musculoskelet Neuronal Interact 2007;7:318-9.
33. Araya K, Fukumoto S, Backenroth R et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 2005;90:5523-7.
34. Frishberg Y, Ito N, Rinat C et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 2007;22:235-42.
35. Nakanishi S, Kazama JJ, Nii-Kono T et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005;67:1171-8.
36. Yamashita H, Yamashita T, Miyamoto M et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol 2004;151:55-60.
37. van BG, Ruinemans-Koerts J, Joosten F et al. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur J Endocrinol 2008;158:431-7.